.jpg)
India's export-oriented information technology outsourcing industry is perhaps more optimistic today about growth prospects than it was in the past five years.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
The Hyderabad-based drugmaker said consolidated net profit rose to Rs Rs 361 crore (Rs 3.61 billion) for the fiscal first quarter ended June, from Rs 336 crore (Rs 3.36 billion) a year earlier.
Now sole contender as L&T Infotech quits race
.jpg)
Global pharmaceutical firms have had a series of patent disputes with Indian makers of generic drugs and several recent Indian rulings have gone against the international giants.
Murthy comes at a time when the company is losing market share, profitability, and has lost control over predictability of the business.
Acquisition to boost its generics business in developed markets.
It, however, is yet to decide on the annual wage rise.
Claims that no customer data was stolen from it.
In the quarter ended March, the company's overall headcount fell by 791 to 84,403.
Move to help employees get more without raising their salary base
Q4 turned out to be a much softer quarter than we expected, and some of the ramp-ups did not happen.
It might take a little longer for demand to pick up in India's IT outsourcing services industry.
Supreme Court will give its verdict on April 1 on whether Swiss giant Novartis AG's cancer treatment drug Glivec deserves a patent in the country not it doesn't.
The US company is driving this strategy through a combination of initiatives, including working with telecom carriers to offer Facebook to users at an affordable rate.
The $100-billion export-driven sector has been vocal on the need to move up the value chain with increased automation, offering services bundled with software products and platforms.
On Tuesday, Nasscom announced at its 21st Leadership Summit that it expected the sector to grow 12-14 per cent in FY14, better than the 10.9 per cent growth it would report for FY13.
Since two cases against clinical trials started in SC, govt is overly cautious.
Infy CEO and MD talks about the factors behind the company's performance in the quarter.
Indian information technology (IT) and businesses process outsourcing (BPO) firms that are heavily dependent on business visas can heave a sigh of relief as the United States Department of Labor (DoL) has decided not to change the Labor Condition Application (LCA) norms for now, said industry sources.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances